share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/17 16:37
Moomoo AI 已提取核心訊息
On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.
On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.
2024年4月17日，生物製藥公司ZyVersa Therapeutics, Inc. 舉行了一次股東特別會議，對幾項關鍵提案進行投票。會議達到了法定人數，代理人約佔已發行股份的39％。主要議程是批准反向股票分割的章程修正案，該修正案以2,058,182票贊成，899,831票反對獲得通過。經批准的修正案允許董事會自行決定以1比2和1比50的比例進行反向股票分割，而無需進一步獲得股東的批准。此外，一項關於休會以徵集更多代理人的提議獲得批准，但由於反向股票拆分獲得了足夠的選票，因此沒有實際意義。董事會已將反向股票拆分比率設定爲1比10，將於美國東部時間2024年4月25日下午 4:01 生效。自2024年4月26日起，ZyVersa Therapeutics的普通股將在拆分後在納斯達克資本市場上市，新的CUSIP編號爲98987D 300。
2024年4月17日，生物製藥公司ZyVersa Therapeutics, Inc. 舉行了一次股東特別會議，對幾項關鍵提案進行投票。會議達到了法定人數，代理人約佔已發行股份的39％。主要議程是批准反向股票分割的章程修正案，該修正案以2,058,182票贊成，899,831票反對獲得通過。經批准的修正案允許董事會自行決定以1比2和1比50的比例進行反向股票分割，而無需進一步獲得股東的批准。此外，一項關於休會以徵集更多代理人的提議獲得批准，但由於反向股票拆分獲得了足夠的選票，因此沒有實際意義。董事會已將反向股票拆分比率設定爲1比10，將於美國東部時間2024年4月25日下午 4:01 生效。自2024年4月26日起，ZyVersa Therapeutics的普通股將在拆分後在納斯達克資本市場上市，新的CUSIP編號爲98987D 300。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息